Besides, individualized mutanome vaccines, an RNA-based poly-neo-epitope approach to mobilize immunity against a spectrum of cancer mutations, were applied to patients in melanoma and obtained a complete response to vaccination in combination with PD-1 blockade therapy (138). This evidence concerns the gene PDCD1 and melanoma.